Safety and efficiency of transplantation of allogenic multipotent stromal cells in surgical treatment of dilatated cardiomyopathy.
Clinical study of intracoronary transplantation of allogenic multipotent bone marrow stromal cells was carried out in patients with severe chronic cardiac failure against the background of dilatated cardiomyopathy. The results indicate that intracoronary injection of allogenic multipotent stromal precursors is a safe procedure. No complications and side effects directly or indirectly related to cell transplantation were recorded during the immediate and delayed postoperative periods. The positive effect of cell transplantation developed from week 1 after transplantation and persisted for 6 months. It manifested in reduction of the level of brain natriuretic peptide and improvement of patient's functional status and quality of life. No appreciable changes in the main echocardiographic values were noted. Transplantation of allogenic multipotent stromal cells is effective as a component of combined therapy for chronic cardiac failure at the stage of preparation to surgery as a "bridge to surgical treatment".